← Eichor
Condition: Clear Cell Renal Cell Cancer Ccrcc Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Clear Cell Renal Cell Cancer Ccrcc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized C
Phase N/A · 1 location(s) · Mingzhao Xiao · NCT06088134
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works
Phase 1/Phase 2 · 11 location(s) · Regeneron Pharmaceuticals · NCT06413680
A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
Phase 2 · 2 location(s) · Stephanie Berg · NCT07123090
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07389629
Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07386158
Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma
Phase 2 · 1 location(s) · Jinling Hospital, China · NCT07571551
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 · 30 location(s) · Calico Life Sciences LLC · NCT04777994
Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma
Phase N/A · 1 location(s) · The Affiliated Hospital of Qingdao University · NCT06916624
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Phase 1/Phase 2 · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT06835972
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
Phase 2 · 1 location(s) · Kelly Fitzgerald, MD · NCT07043608
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Car
Phase 3 · 134 location(s) · Arcus Biosciences, Inc. · NCT07011719
Combination of Toripalimab and JS004 Therapy for ccRCC
Phase 2 · 1 location(s) · Fudan University · NCT06690697
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Phase 1/Phase 2 · 12 location(s) · GI Innovation, Inc. · NCT04977453
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Phase 1 · 122 location(s) · Exelixis · NCT05176483
A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcin
Phase 1 · 1 location(s) · PeptiDream Inc. · NCT07688187
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Phase 1/Phase 2 · 5 location(s) · Oncorena AB · NCT05287945
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for A
Phase 1/Phase 2 · 24 location(s) · Regeneron Pharmaceuticals · NCT03972657
68Ga-NYM096 PET/ CT for the Detection of ccRCC in Presurgical Patients With Complex Cystic Renal Leision
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT06949215
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
Phase 3 · 8 location(s) · Telix Pharmaceuticals (Innovations) Pty Limited · NCT06750419
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Phase 1 · 38 location(s) · Kura Oncology, Inc. · NCT06026410
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Phase 1 · 6 location(s) · Pliant Therapeutics, Inc. · NCT06270706
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
NA · 1 location(s) · Peking University First Hospital · NCT07557225
A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Phase 1 · 22 location(s) · Incyte Corporation · NCT07195916
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05665361
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerabili
Phase 1/Phase 2 · 10 location(s) · ITM Oncologics GmbH · NCT05706129
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Ce
Phase 1 · 11 location(s) · Neomorph, Inc · NCT07300241
68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT06613269
Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
Phase 3 · 5 location(s) · Telix Pharmaceuticals (Innovations) Pty Limited · NCT07197580
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Expres
Phase 1 · 5 location(s) · Novelty Nobility, Inc. · NCT06805825
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.